ATORVASTATIN IN THE PREVENTION OF CARDIOVASCULAR DISEASES IN FEMALE PATIENTS WITH RHEUMATOID ARTHRITIS
- Autores: Smakotina S.A1, Zelendinova A.R1, Bondareva I.N2, Fomina N.V1, Berns S.A3, Golikova A.A3
-
Afiliações:
- Kemerovo State Medical University
- Kemerovo Regional Clinical Hospital
- FSBEI HE MSMSU n.a. A.I. Evdokim of RMH
- Edição: Nº 9 (2017)
- Páginas: 44-49
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289868
- ID: 289868
Citar
Texto integral
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Palavras-chave
Texto integral
Sobre autores
S. Smakotina
Kemerovo State Medical University
A. Zelendinova
Kemerovo State Medical University
I. Bondareva
Kemerovo Regional Clinical Hospital
N. Fomina
Kemerovo State Medical University
S. Berns
FSBEI HE MSMSU n.a. A.I. Evdokim of RMH
Email: svbems@yandex.ru
MD, Prof. at the Department of Interna! Diseases of the Stomatological Faculty
A. Golikova
FSBEI HE MSMSU n.a. A.I. Evdokim of RMH
Bibliografia
- Клиническая ревматология. Руководство для практических врачей / Под ред. В.И. Мазурова. СПб., 2001.416 с.
- Герасимова Е.В., Попкова Т.В., Новикова Д.С. и др. 10-летний риск развития сердечно-сосудистых осложнений у больных ревматоиднымартритом. Тер. архив 201;83(5):9-14.
- Дядык А.И., Багрий А.Э., Стуликова Е.Л. и др. Применение аторвастатина у больных ревматоидным артритом. Украин. ревматол. журн. 2006;3(25):38-41.
- Новикова Д.С., Попкова Т.В., Насонов Е.Л. Снижение кардиоваскулярного риска при ревматоидном артрите: двойная польза статинов. Научно-практич. ревматология. 2010;48(6):61-71.
- Попкова Т.В., Новикова Д.С., Герасимова Е.В. и др. Значение факторов риска в прогнозировании клинических проявлений атеросклероза при СКВ и РА. Сб. матер. V съезда ревматологов России. М., 2009. 91 с.
- Попкова Т.В., Новикова Д.С., Насонов Е.Л. Атеросклероз при ревматических заболеваниях. В кн.: Ревматология: клинические рекомендации. M., 2010. С. 678-702.
- Попкова Т.В., Новикова Д.С., Новиков А.А. и др. Роль нарушений в системе транспорта холестерина крови в развитии атеросклероза при ревматоидном артрите. Научно-практич. ревматология. 2007;5:4-10.
- Avina-Zubieta J.A., Thomas J., Sadatsafavi M., Lehman A.J., Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012;71(9):1524-29.
- Bisoendial R., Stroes E., Kastelein J., Tak P.P. Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins. Nat. Rev. Rheum. 2010;6(3):157-64.
- Van Halm V.P., Nielen M.J., Nurmohamed M.T., VanSchaardenburg D., Reesink H.W., Voskuyl A.E., Twisk J.W., Van de Stadt R.J., de Koning M.H., Habibuw M.R., Van der Horst-Bruinsma I.E., Dijkmans B.A. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann. Rheum. Dis. 2006;3:1-5.
- Curtis J., John A., Baser O. Frequency of lipid testing in patients with rheumatoid arthritis: a retrospective database analysis. Arthr. Rheum. 2009;60(10):516.
- Nielen M.J., van Halm V.P., Nurmohamed M.T., et al. Rheumatoid arthritis is preceded by a preclinical phase, characterized by increased C-reactive protein levels and a more atherogenic lipid profile. Arthr. Rheum. 2003; 48:344.
- Peters M.J., Symmons D.P., McCarey D.W., Dijkmans B.A., Nicola P., Kvien T.K., McInnes I.B., Haentzschel H., Gonzalez-Gay M.A., Provan S., Semb A., Sidiropoulos P., Kitas G., Smulders Y.M., Soubrier M., Szekanecz Z., Sattar N., Nurmohamed M.T. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis -TASK FORCE «Cardiovascular risk management in RA». Ann. Rheum. Dis. 2010;69(2):325-31.
- Gazi I.F., Boumpas D.T., Mikhailidis D.P., Ganotakis E.S. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin. Exp. Rheum. 2007; 25:102-11.
- Nurmohamed M., Dijkmans B. Dyslipidemia, statins and rheumatoid arthritis. Ann. Rheum. Dis. 2009;68:453-55.
- Lindhardsen J., Ahlehoff O., Gislason G., Madsen O.R., Olesen J.B., Torp-Pedersen C., Hansen PR. The risk of miocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danich nationwide cohort study. Ann. Rheum. Dis. 2011;70:929-34.
- Toms T.E., Panoulas V.F., Douglas K.M., Griffiths H., Sattar N., Smith J.P., Symmons D.P., Nightingale P., Metsios G.S., Kitas G.D. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial under treatment of lipid associated cardiovascular risk? Ann. Rheum. Dis. 2009; [Epub. ahead of print].
- Lien L.M., Hsieh Y.C. Association of blood active matrix metalloproteinase-3 with carotid plaque score from a community population in Taiwan. Atherosclerosis. 2010;212(2):595-600.
- Maradit-Kremers H., Crowson C.S., Therneau T.M., Roger V.L., Gabriel S.E. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients. A population-based cohort study. Arthr. Rheum. 2008;58(8): 2268-74.
- Meune C., Touze E., Trinqurte L., Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analisis of cohort studies. Rheumatology. 2009;48(10):1309-13.
- Phan K., Gomez Y.H., Elbaz L., Daskalopoulou S.S. Statin treatment no-adherence and discontinuation: clinical implications and potential solutions. Curr. Pharm. Des. 2014;20(40):6314-24.
- Okamoto H., Koizumi K., Kamitsuji S., Inoue E., Hara M., Tomatsu T., Kamatani N., Yamanaka H. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J. Rheumatol. 2007;34: 964-68.
- Hollan I., Dessein PH., Ronda N., Wasko M.C., Svenungsson E., Agewall S., Cohen-Tervaert J.W., Maki-Petaja K., Grundtvig M., Karpouzas G.A., Meroni P.L. Prevention of cardiovascular disease in rheumatoid arthritis. Autoimmun Rev. 2015;14(10):952-69.